Pharming Group is a small-cap biotech below the minimum investable market cap of $1 billion, with declining revenue of -8% but an exceptional Piotroski score of 8 out of 9, strong free cash flow conversion, and analyst targets implying 128% upside if momentum recovers.
Thesis pillars
- Below Investable Market Cap↓Deteriorating
- Revenue Decline Momentum Weakness↑Improving
- High Piotroski Cashflow Quality↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026
Pharming Group N.V. (PHAR) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $12.26, but acceptable to hold if already in. Reasons: Overbought (RSI 79); Below 200-MA, MA slope -7.0%/30d (confirmed downtrend).
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1... Read more
Hold if already holding. Not a fresh buy at $12.26, but acceptable to hold if already in. Reasons: Overbought (RSI 79); Below 200-MA, MA slope -7.0%/30d (confirmed downtrend). Chart setup: Death cross but MACD improving, RSI 79. Maintain position. Not compelling to add more. Score 6.5/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-10-29Recent Developments — Pharming Group N.V.
Latest news
- NEWS Oppenheimer reiterates Pharming Group stock rating at Outperform By Investing.com - Investing.com India — Investing.com India positive
- NEWS Oppenheimer reiterates Pharming Group stock rating at Outperform By Investing.com - Investing.com Nigeria — Investing.com Nigeria positive
- NEWS Oppenheimer reiterates Pharming Group stock rating at Outperform By Investing.com - Investing.com Canada — Investing.com Canada positive
- NEWS Oppenheimer reiterates Pharming Group stock rating at Outperform By Investing.com - Investing.com UK — Investing.com UK positive
- NEWS Pharming Group (ENXTAM:PHARM) Stock Faces A Q3 Earnings Valuation Gap - Yahoo Finance — Yahoo Finance neutral
Generated 2026-10-29T11:53:51Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $12.26, but acceptable to hold if already in. Reasons: Overbought (RSI 79); Below 200-MA, MA slope -7.0%/30d (confirmed downtrend). Chart setup: Death cross but MACD improving, RSI 79. Maintain position. Not compelling to add more. Analyst target $29.20 (+138.2%), stop $11.40 (−7.5%), A.R:R 9.2:1. Score 6.5/10, moderate confidence.
Analyst target: $29.20 (+138.2% upside). Analyst target $29.20 (+138.2%), stop $11.40 (−7.5%), A.R:R 9.2:1. Stop-loss: $11.40.
Overbought (RSI 79); Below 200-MA, MA slope -7.0%/30d (confirmed downtrend).
Pharming Group N.V. trades at a P/E of 38.3 (forward 68.1). TrendMatrix value score: 5.7/10. Verdict: Hold.
13 analysts cover PHAR with a consensus score of 4.4/5. Average price target: $34.
What does Pharming Group N.V. do?Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and...
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kd inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3Kd inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.